Baidu
map

陈竺:感染性疾病防控需加大国际间合作

2012-10-30 网络 网络

  10月26日,在第13届亚太临床微生物与感染病会议上,卫生部部长陈竺针对感染性疾病防控提出三点建议,要求加强国际科技交流,加大国际间科研合作,加强科学技术转化运用,共同推动感染性疾病的防治工作。   感染性疾病严重危害人类健康的疾病,近年来各种新发、突发感染性疾病不断出现,如SARS、新冠状病毒感染、H1N1流感、禽流感、肠出血大肠杆菌感染等,而艾滋病、病毒性肝炎等仍然是重大科学难题。对此,

  10月26日,在第13届亚太临床微生物与感染病会议上,卫生部部长陈竺针对感染性疾病防控提出三点建议,要求加强国际科技交流,加大国际间科研合作,加强科学技术转化运用,共同推动感染性疾病的防治工作。

  感染性疾病严重危害人类健康的疾病,近年来各种新发、突发感染性疾病不断出现,如SARS、新冠状病毒感染、H1N1流感、禽流感、肠出血大肠杆菌感染等,而艾滋病、病毒性肝炎等仍然是重大科学难题。对此,陈竺指出,由于现代社会生活方式改变、城市化进展不断加快,人口流动、气候变化以及抗菌药物不合理使用,感染性疾病防控工作面临着各种困难,攻克这些难题需要多学科、全方位和国际性的合作和交流,需要开展深入和广泛的科学研究,加强信息沟通与共享,提高对感染性疾病的预警与反应能力。

  陈竺指出,亚太地区作为人口稠密的新型发展地区,感染性疾病防治工作更是任重道远。对此他提出三点建议,一是进一步加强国际科技交流,充分利用国际学术会议等,搭建科学交流平台,凝聚各国专家和学者的智慧,充分分享感染性疾病的防控经验和研究成果;二是加大国际科研合作,力争在感染性疾病预防和治疗的技术上取得重大突破;三是加强科学技术转化运用,在形成专家共设基础上,进一步完善感染性疾病防治的指南和规范。

  乙肝是患者最多的感染性疾病之一。中华医学会感染病学会主任委员、中国工程院李兰娟院士指出,经过20年的努力,中国乙肝病毒感染的情况得到改善,1992年中国乙肝表面抗原携带率为9.75%,但2010年的最新数据显示,中国乙肝表面抗原携带率已降至6.83%。在中国,新生儿乙肝疫苗三针覆盖率已达到90%,世界卫生组织评估认为:中国慢性乙肝感染率至少在5岁以下人群中已下降到1%以下,乙肝疫苗是预防乙肝病毒感染与肝炎发生的最有效方法,中国预防乙肝感染的成功经验可为世界其它国家提供借鉴。

  本次大会由中华医学会、中华预防医学会、中国药学会和中国医师协会共同承办。全国人大常委会副委员长桑国卫出席会议。



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1665822, encodeId=d7ed16658221f, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Mon Nov 19 02:15:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035365, encodeId=1cbd203536582, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jun 14 07:15:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655314, encodeId=6f9a1655314d3, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Mon Jul 29 20:15:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404589, encodeId=6489140458971, content=<a href='/topic/show?id=999b98080a7' target=_blank style='color:#2F92EE;'>#陈竺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98080, encryptionId=999b98080a7, topicName=陈竺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83d92488219, createdName=zhaohui6732, createdTime=Thu Nov 01 01:15:00 CST 2012, time=2012-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1665822, encodeId=d7ed16658221f, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Mon Nov 19 02:15:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035365, encodeId=1cbd203536582, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jun 14 07:15:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655314, encodeId=6f9a1655314d3, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Mon Jul 29 20:15:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404589, encodeId=6489140458971, content=<a href='/topic/show?id=999b98080a7' target=_blank style='color:#2F92EE;'>#陈竺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98080, encryptionId=999b98080a7, topicName=陈竺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83d92488219, createdName=zhaohui6732, createdTime=Thu Nov 01 01:15:00 CST 2012, time=2012-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1665822, encodeId=d7ed16658221f, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Mon Nov 19 02:15:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035365, encodeId=1cbd203536582, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jun 14 07:15:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655314, encodeId=6f9a1655314d3, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Mon Jul 29 20:15:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404589, encodeId=6489140458971, content=<a href='/topic/show?id=999b98080a7' target=_blank style='color:#2F92EE;'>#陈竺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98080, encryptionId=999b98080a7, topicName=陈竺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83d92488219, createdName=zhaohui6732, createdTime=Thu Nov 01 01:15:00 CST 2012, time=2012-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1665822, encodeId=d7ed16658221f, content=<a href='/topic/show?id=978d53318de' target=_blank style='color:#2F92EE;'>#感染性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53318, encryptionId=978d53318de, topicName=感染性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97fa26021282, createdName=12498fa0m19暂无昵称, createdTime=Mon Nov 19 02:15:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035365, encodeId=1cbd203536582, content=<a href='/topic/show?id=718fe07371e' target=_blank style='color:#2F92EE;'>#疾病防控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70737, encryptionId=718fe07371e, topicName=疾病防控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jun 14 07:15:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655314, encodeId=6f9a1655314d3, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Mon Jul 29 20:15:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404589, encodeId=6489140458971, content=<a href='/topic/show?id=999b98080a7' target=_blank style='color:#2F92EE;'>#陈竺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98080, encryptionId=999b98080a7, topicName=陈竺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83d92488219, createdName=zhaohui6732, createdTime=Thu Nov 01 01:15:00 CST 2012, time=2012-11-01, status=1, ipAttribution=)]
    2012-11-01 zhaohui6732
Baidu
map
Baidu
map
Baidu
map